April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant

April 11, 2025

Early Antibiotics Linked to Asthma, Eczema

Researchers found early-life antibiotic use was linked to increased risk of asthma and eczema, but not most other immune diseases, after adjusting for familial factors.

Conexiant

April 10, 2025

FDA to Pilot Animal-Free Models

"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use."

Reuters

April 09, 2025

Secukinumab Shows Long-Term Efficacy in HS

Secukinumab demonstrated sustained clinical benefits, with 76.5% of patients maintaining hidradenitis suppurativa clinical response at week 104, study shows.

Conexiant

April 08, 2025

Mediterranean Diet, Exercise Boost Bone Health

Mediterranean diet combined with physical activity helps prevent age-related bone mineral density loss in women with metabolic syndrome.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant

April 02, 2025

Cost-Effectiveness of Shoulder Arthroplasties Analyzed

Total shoulder arthroplasty was found to be more cost-effective than hemiarthroplasty.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Cold Plunges: A Cellular Reset?

New research shows that 1 week of daily cold-water immersion enhances autophagy and reduces cell death signals.

Conexiant